Ilorasertib, with the CAS number 1227939-82-3, is a small molecule inhibitor primarily targeting the protein kinase activity of certain members of the Aurora kinase family, which play a crucial role in cell division and mitosis. This compound is characterized by its potential application in cancer therapy, particularly in the treatment of various malignancies where aberrant cell division is a hallmark. Ilorasertib exhibits selective inhibition, which may lead to reduced side effects compared to less specific chemotherapeutic agents. Its mechanism of action involves disrupting the normal function of Aurora kinases, thereby inducing cell cycle arrest and apoptosis in cancer cells. The compound is typically administered in a clinical setting, and its efficacy and safety profile are evaluated through rigorous clinical trials. As with many targeted therapies, the development of resistance and the identification of biomarkers for patient selection are critical areas of ongoing research. Overall, Ilorasertib represents a promising avenue in the field of targeted cancer therapies.

Ilorasertib

1227939-82-3: Ilorasertib, with the CAS number 1227939-82-3, is a small molecule inhibitor primarily targeting the protein kinase activity of certain members of the Aurora kinase family, which play a crucial role in cell division and mitosis. This compound is characterized by its potential application in cancer therapy, particularly in the treatment of various malignancies where aberrant cell division is a hallmark. Ilorasertib exhibits selective inhibition, which may lead to reduced side effects compared to less specific chemotherapeutic agents. Its mechanism of action involves disrupting the normal function of Aurora kinases, thereby inducing cell cycle arrest and apoptosis in cancer cells. The compound is typically administered in a clinical setting, and its efficacy and safety profile are evaluated through rigorous clinical trials. As with many targeted therapies, the development of resistance and the identification of biomarkers for patient selection are critical areas of ongoing research. Overall, Ilorasertib represents a promising avenue in the field of targeted cancer therapies.

<p>Ilorasertib (ABT-348) inhibits Aurora kinases A/B/C &amp; RET, PDGFRβ, Flt1 (IC50: 1-120 nM).</p>

CAS 1227939-82-3

Ilorasertib

Ilorasertib

Ref: 54-BUP09072

Ilorasertib

Ref: TM-TQ0059

ABT-348

Ref: 4Z-A-181001